Mehmet Taner Karaoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehmet Taner Karaoğlu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Murat Kaplan
İzmir/Bornova Veteriner Kontrol Enstitüsü
2 shared publications - Tugba Tezcan
Department of Analytical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey
2 shared publications - Alireza Hanifehnezhad
Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey
1 shared publication - Asuman Bozkir
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
1 shared publication - Ateş Kara
Division of Pediatric Infectious Diseases, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Türkiye
1 shared publication - Aykut Ozkul
Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 28482
Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity
Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR−/− mice (n = 4 per group) for protective efficacy using antigenically homologous or heterologous prime-boost regimens. Animals received priming immunization on day 0 and booster on day 28 followed by lethal CCHFV challenge (1000 TCID50) on day 42. Immune responses were characterized via ELISA, virus neutralization tests, cytokine profiling, ELISpot, and flow cytometry. Post-challenge survival, viral loads in target organs, and safety profiles were assessed. All AdV5 constructs successfully expressed the target antigens and induced rapid seroconversion, with 75–100% of animals exhibiting antibody responses after priming with a single dose. The dual-antigen formulations elicited the strongest Th1-polarized responses particularly nucleoprotein + Gc combinations with interferon-γ production more than 30-fold above baseline and preferential expansion of CD4+ T helper cells (60–70% of CD3+ populations). Neutralizing antibody titers varied across groups (80–160 arbitrary units in high responders) but did not directly correlate with survival outcomes. After lethal challenge, multiple vaccine formulations achieved 100% survival throughout the 10-day observation period, while only control groups showed no protection. All vaccinated animals demonstrated significant viral load reduction of two to four logs in liver and spleen tissues, with some achieving complete clearance of the virus. Furthermore, no off-target vector dissemination was detected in examined tissues confirming safety profile of the constructs. Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations. Sterilizing immunity was observed in some animals, along with evidence that protection operates through multiple immune mechanisms including both neutralizing and non-neutralizing antibody-mediated pathways. These results strongly support further clinical development of AdV5-based CCHFV vaccines, with multiple formulation strategies showing high efficacy and providing flexibility for clinical advancement. GMP-compatible production methods have been successfully implemented for these candidates, supporting their advancement toward non-human primate studies and Phase I clinical trials.
- 11 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 28482
Open AccessDual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity
Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR−/− mice (n = 4 per group) for protective efficacy using antigenically homologous or heterologous prime-boost regimens. Animals received priming immunization on day 0 and booster on day 28 followed by lethal CCHFV challenge (1000 TCID50) on day 42. Immune responses were characterized via ELISA, virus neutralization tests, cytokine profiling, ELISpot, and flow cytometry. Post-challenge survival, viral loads in target organs, and safety profiles were assessed. All AdV5 constructs successfully expressed the target antigens and induced rapid seroconversion, with 75–100% of animals exhibiting antibody responses after priming with a single dose. The dual-antigen formulations elicited the strongest Th1-polarized responses particularly nucleoprotein + Gc combinations with interferon-γ production more than 30-fold above baseline and preferential expansion of CD4+ T helper cells (60–70% of CD3+ populations). Neutralizing antibody titers varied across groups (80–160 arbitrary units in high responders) but did not directly correlate with survival outcomes. After lethal challenge, multiple vaccine formulations achieved 100% survival throughout the 10-day observation period, while only control groups showed no protection. All vaccinated animals demonstrated significant viral load reduction of two to four logs in liver and spleen tissues, with some achieving complete clearance of the virus. Furthermore, no off-target vector dissemination was detected in examined tissues confirming safety profile of the constructs. Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations. Sterilizing immunity was observed in some animals, along with evidence that protection operates through multiple immune mechanisms including both neutralizing and non-neutralizing antibody-mediated pathways. These results strongly support further clinical development of AdV5-based CCHFV vaccines, with multiple formulation strategies showing high efficacy and providing flexibility for clinical advancement. GMP-compatible production methods have been successfully implemented for these candidates, supporting their advancement toward non-human primate studies and Phase I clinical trials.
- Open Access
- 24 January 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (6) , 958
Correction: A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2
Correction for ‘A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2’ by Ezgi Salmanli et al., Anal. Methods, 2024, https://doi.org/10.1039/d3ay01870a.
- 24 January 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (6) , 958
Open AccessCorrection: A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2
Correction for ‘A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2’ by Ezgi Salmanli et al., Anal. Methods, 2024, https://doi.org/10.1039/d3ay01870a.
- 8 January 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (4) , 551-557
A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2
Expression of a recombinant VP2 antigen in E. coli and the process on a cLFA system for total antibody detection of canine parvovirus-2.
- 8 January 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (4) , 551-557
A novel lateral flow immunochromatographic assay using a recombinant VP2 antigen for total antibody detection of canine parvovirus-2
Expression of a recombinant VP2 antigen in E. coli and the process on a cLFA system for total antibody detection of canine parvovirus-2.
- 3 October 2021
- Published by Springer Nature in Archives of Virology
- Vol. 166 (12) , 3343-3356
Investigation of betanodavirus in sea bass (Dicentrarchus labrax) at all production stages in all hatcheries and on selected farms in Turkey
Viral nervous necrosis (VNN) is one of the most important problems in sea bass culture. Although there have been many studies on detection and molecular characterization of betanodavirus, the causative agent of VNN, there has been little focus on understanding its prevalence to create epidemiological maps. The purpose of this study was to investigate the prevalence of betanodavirus in active sea bass hatcheries and on selected farms in Turkey by RT-qPCR. A total of 2460 samples, including fertilized eggs, prelarvae, postlarvae, fry, and fingerlings, were collected from 16 hatcheries to cover all production stages. A total of 600 sea bass were also collected from 20 farms. Betanodavirus was detected in one hatchery (1/16) in fingerling-sized sea bass, and the prevalence of betanodavirus at the hatchery level was calculated to be 6.25%. Betanodavirus was also detected on one farm (1/20) in fingerling-sized sea bass, and the prevalence of betanodavirus at the farm level was calculated to be 5%. Virus isolation initially could not be achieved in E-11 cells, but later, SSN-1 cells were used successfully. Partial genome sequence analysis of the RNA1 and RNA2 segments of the viruses revealed that they were of the red-spotted grouper nervous necrosis virus genotype, which is endemic in the Mediterranean basin. The absence of mortality related to VNN in the hatcheries and on the farms, the healthy appearance of the sea bass, the low viral load detected, and the results of retrospective epidemiological studies indicated that the infection was subclinical. Not detecting betanodavirus in other age groups where biosecurity was implemented indicates that there was no active infection. In light of these findings, it can be concluded that there was no betanodavirus circulating in hatcheries, and the virus might have been of seawater origin.
- 3 October 2021
- Published by Springer Nature in Archives of Virology
- Vol. 166 (12) , 3343-3356
Investigation of betanodavirus in sea bass (Dicentrarchus labrax) at all production stages in all hatcheries and on selected farms in Turkey
Viral nervous necrosis (VNN) is one of the most important problems in sea bass culture. Although there have been many studies on detection and molecular characterization of betanodavirus, the causative agent of VNN, there has been little focus on understanding its prevalence to create epidemiological maps. The purpose of this study was to investigate the prevalence of betanodavirus in active sea bass hatcheries and on selected farms in Turkey by RT-qPCR. A total of 2460 samples, including fertilized eggs, prelarvae, postlarvae, fry, and fingerlings, were collected from 16 hatcheries to cover all production stages. A total of 600 sea bass were also collected from 20 farms. Betanodavirus was detected in one hatchery (1/16) in fingerling-sized sea bass, and the prevalence of betanodavirus at the hatchery level was calculated to be 6.25%. Betanodavirus was also detected on one farm (1/20) in fingerling-sized sea bass, and the prevalence of betanodavirus at the farm level was calculated to be 5%. Virus isolation initially could not be achieved in E-11 cells, but later, SSN-1 cells were used successfully. Partial genome sequence analysis of the RNA1 and RNA2 segments of the viruses revealed that they were of the red-spotted grouper nervous necrosis virus genotype, which is endemic in the Mediterranean basin. The absence of mortality related to VNN in the hatcheries and on the farms, the healthy appearance of the sea bass, the low viral load detected, and the results of retrospective epidemiological studies indicated that the infection was subclinical. Not detecting betanodavirus in other age groups where biosecurity was implemented indicates that there was no active infection. In light of these findings, it can be concluded that there was no betanodavirus circulating in hatcheries, and the virus might have been of seawater origin.
- Open Access
- 15 September 2018
- Published by Ege University Faculty of Fisheries in Ege Journal of Fisheries and Aquatic Sciences
- Vol. 35 (3) , 353-360
National and international legislations of combating viral fish diseases
The aim of this review is provide up-to-date information on the fighting against the viral fish diseases and their notification in our country which is very important in European and world aquaculture. Turkey has developed and organized fisheries facilities and significant role in production and export in Europe. As well as the well understanding of impotance of the viral fish diseases that make up the vast majority of fish diseases and cause large economic losses, the knowledge and understanding of control and combat measures provide important contributions to the development of the industry. This review, which includes national and international legislation, aims to reach all stakeholders of the sector and to increase current awareness.
- 15 September 2018
- Published by Ege University Faculty of Fisheries in Ege Journal of Fisheries and Aquatic Sciences
- Vol. 35 (3) , 353-360
Open AccessNational and international legislations of combating viral fish diseases
The aim of this review is provide up-to-date information on the fighting against the viral fish diseases and their notification in our country which is very important in European and world aquaculture. Turkey has developed and organized fisheries facilities and significant role in production and export in Europe. As well as the well understanding of impotance of the viral fish diseases that make up the vast majority of fish diseases and cause large economic losses, the knowledge and understanding of control and combat measures provide important contributions to the development of the industry. This review, which includes national and international legislation, aims to reach all stakeholders of the sector and to increase current awareness.